Tahar van der Straaten
Overview
Explore the profile of Tahar van der Straaten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
666
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Lemos C, Giovannetti E, Zucali P, Assaraf Y, Scheffer G, der Straaten T, et al.
Pharmacogenomics
. 2011 Feb;
12(2):159-70.
PMID: 21332310
Aims: The current study investigates whether or not functional polymorphisms in the ATP-binding cassette transporter gene ABCG2 might affect gefitinib activity and/or toxicity in non-small-cell lung cancer (NSCLC) patients. Materials...
32.
Baak-Pablo R, Dezentje V, Guchelaar H, der Straaten T
J Mol Diagn
. 2010 Sep;
12(6):746-9.
PMID: 20847277
DNA isolated from formalin-fixed paraffin-embedded (FFPE) tissue is often fragmented and cross-linked and is therefore difficult to genotype. To enable this source of DNA for genotyping analysis using Taqman probes,...
33.
Pander J, Gelderblom H, Antonini N, Tol J, van Krieken J, der Straaten T, et al.
Eur J Cancer
. 2010 Apr;
46(10):1829-34.
PMID: 20418097
Background: Next to KRAS mutation status, additional predictive markers are needed for the response to cetuximab in patients with metastatic colorectal cancer (mCRC). Previous studies indicated that germline polymorphisms in...
34.
der Straaten T, van Schaik R
Curr Pharm Des
. 2010 Mar;
16(2):231-7.
PMID: 20214624
With the exponential increase in publications on DNA markers explaining and/or predicting response to drug therapy, the potential of pharmacogenetic testing of individual patients to optimize drug treatment is expanding....
35.
Steeghs N, Mathijssen R, Wessels J, de Graan A, der Straaten T, Mariani M, et al.
Invest New Drugs
. 2010 Feb;
29(5):953-62.
PMID: 20182906
Objectives: Danusertib is a serine/threonine kinase inhibitor of multiple kinases, including aurora-A, B, and C. This explorative study aims to identify possible relationships between single nucleotide polymorphisms in genes coding...
36.
Kooloos W, Wessels J, der Straaten T, Allaart C, Huizinga T, Guchelaar H
Pharmacogenomics
. 2010 Feb;
11(2):163-75.
PMID: 20136356
Aims: Clinical response to methotrexate (MTX) treatment differs among rheumatoid arthritis patients. Genetic variation can partly account for this phenomenon. In this study, functional polymorphisms in genes related to the...
37.
Dervieux T, Wessels J, der Straaten T, Penrod N, Moore J, Guchelaar H, et al.
Pharmacogenet Genomics
. 2009 Oct;
19(12):935-44.
PMID: 19858780
Objective: As no single nucleotide polymorphism has emerged as pivotal to predict the lack of efficacy and dose-limiting toxicities to methotrexate (MTX), we evaluated the contribution of gene-gene interactions to...
38.
van Erp N, Eechoute K, van der Veldt A, Haanen J, Reyners A, Mathijssen R, et al.
J Clin Oncol
. 2009 Aug;
27(26):4406-12.
PMID: 19667267
Purpose: To identify genetic markers in the pharmacokinetic and pharmacodynamic pathways of sunitinib that predispose for development of toxicities: thrombocytopenia, leukopenia, mucosal inflammation, hand-foot syndrome, and any toxicity according to...
39.
Kooloos W, Wessels J, der Straaten T, Huizinga T, Guchelaar H
Drug Discov Today
. 2009 Jun;
14(17-18):837-44.
PMID: 19524701
Pharmacogenetics aims to identify genetic variation to predict drug response or to establish an individual optimal dose. Classically, explorative pharmacogenetic studies are performed concerning a limited number of SNPs in...
40.
Press R, Ploeger B, den Hartigh J, der Straaten T, van Pelt J, Danhof M, et al.
Ther Drug Monit
. 2009 Mar;
31(2):187-97.
PMID: 19258929
To prevent acute rejection episodes, it is important to reach adequate tacrolimus (TRL) exposure early after kidney transplantation. With a better understanding of the high variability in the pharmacokinetics of...